Palvella Therapeutics, Inc. (PVLA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-96.8%

$4.71

vs $146.33 price

Levered DCF

$5.10

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

33.98

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
P/E	-28.21×	-1.53×	1.15×	-0.57×	-0.3×	0×
P/B	42.09×	0.43×	-5.56×	-0.68×	0.27×	0×
P/S	0×	0×	0×	0.61×	0.44×	0×
EV / EBITDA	-31.21×	4.34×	0.76×	0.01×	2.06×	0×
Gross margin	0.0%	0.0%	0.0%	89.3%	92.5%	0.0%
Operating margin	0.0%	0.0%	0.0%	-167.8%	-165.0%	0.0%
Net margin	0.0%	0.0%	0.0%	-128.5%	-145.6%	0.0%
Current ratio	5.2×	7.33×	3.2×	2.86×	2.52×	3.42×
Debt / equity	0.02×	0×	0×	0×	0.29×	0.55×
Interest coverage	-6.63×	-3.26×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Return on equity	-149.1%	-27.8%	-481.7%	143.6%	-90.1%	0.0%
Return on invested capital	-79.7%	-18.5%	-228.8%	-404.7%	-49.8%	0.0%
Return on assets	-70.0%	-19.8%	247.6%	-201.4%	-29.8%	0.0%
Free cash flow yield	-2.1%	-40.6%	-63.6%	-93.8%	-62.8%	0.0%
Earnings yield	-3.5%	-65.3%	86.7%	-210.4%	-333.5%	0.0%
Enterprise value	$1.1B	-$56.9M	$14.2M	-$237K	-$89.2M	-$53.5M
Net debt / EBITDA	1.6×	6.37×	-0.39×	0.53×	2.37×	0×
Cash conversion cycle (days)	0	0	0	-418	-1,288	0